Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BCL9 | O00512 | 9/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 9/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21409448 | 0.94 | HSD11B1 (0.42) | KDM4EALDH1A1HSD11B1NR3C1PGR | |
| Hydrochloric Acid SCHEMBL30008988 | 0.93 | HSD11B1 (0.41) | KDM4EALDH1A1HSD11B1NR3C1PGR | |
| Hydrochloric Acid SCHEMBL23122705 | 0.93 | HSD11B1 (0.41) | KDM4EALDH1A1HSD11B1NR3C1PGR | |
| Trifluoroacetic Acid SCHEMBL31255728 | 0.90 | PKM (0.46) | PKMKDM4EALDH1A1SOS1HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL30009630 | 0.90 | PKM (0.40) | PKMKDM4EALDH1A1SOS1HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL31255479 | 0.90 | PKM (0.57) | PKMKDM4EALDH1A1SOS1NR3C1 | |
| Trifluoroacetic Acid SCHEMBL31255582 | 0.89 | PKM (0.45) | PKMKDM4EALDH1A1SOS1HSD11B1 | |
| SCHEMBL21409284 | 0.88 | NR3C1 (0.42) | KDM4EALDH1A1HSD11B1NR3C1PGR | |
| SCHEMBL23134536 | 0.86 | NR3C1 (0.42) | KDM4EALDH1A1HSD11B1NR3C1PGR | |
| SCHEMBL31255602 | 0.86 | L3MBTL3 (0.44) | KDM4EALDH1A1HSD11B1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2025-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | BTK, ABL1, LYN | PKM 1857/4885KDM4E 197/4885ALDH1A1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.